Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma
This Expanded Access (EAP) Protocol pertains to the provision of treatment by use of an investigational product. Such access may be considered for patients with serious/life-threatening diseases or conditions, where there are no alternative treatments or where alternative treatments have been exhausted. Cilta-cel OOS does not meet the commercial release specifications of CARVYKTI and is not available via the local health care system in the country where the treatment is requested.
Adult
Treatment
University of Colorado Hospital
Jonathan Gutman, MD
Protocol Number: 23-0111
More information available at ClinicalTrials.gov: NCT05346835
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers